RD-23
RD-23 is an orally active and selective RET PROTAC degrader, with DC50 values of 5.6 nM and 11.7 nM against RETWT and RETG810C mutants, respectively. RD-23 inhibits purified RET kinase activity with an IC50 of 0.371 nM. RD-23 suppresses the activation of downstream Shc signaling and induces apoptosis. RD-23 can be used for the research of RET-related cancers.
(Pink: RET ligand (HY-168868); Blue: Cereblon ligand (HY-43722); Black: linker (HY-W010642)).
For research use only. We do not sell to patients.
- CAS No.: 3053537-06-4
- Formula: C52H56N12O4
- Molecular Weight:913.08
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All PROTACs Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
Cereblon |
In Vitro
RD-23 potently inhibits the proliferation of Ba/F3-KIF5B-RET cells with an IC50 of 2.6 nM[1].
RD-23 potently inhibits the proliferation of Ba/F3-KIF5B-RETV804M cells with an IC50 of 5.2 nM[1].
RD-23 potently inhibits the proliferation of Ba/F3-KIF5B-RETG810C cells with an IC50 of 5.3 nM[1].
RD-23 inhibits the proliferation of Ba/F3-KIF5B-RETG810R cells with an IC50 of 165.2 nM[1].
RD-23 inhibits the proliferation of Ba/F3-KIF5B-RETG810S cells with an IC50 of 22.6 nM[1].
RD-23 potently inhibits the proliferation of Ba/F3-CCDC6-RET cells with an IC50 of 2.4 nM[1].
RD-23 potently inhibits the proliferation of Ba/F3-CCDC6-RETV804M cells with an IC50 of 4.5 nM[1].
RD-23 potently inhibits the proliferation of Ba/F3-CCDC6-RETG810C cells with an IC50 of 6.5 nM[1].
RD-23 inhibits the proliferation of Ba/F3-CCDC6-RETG810R cells with an IC50 of 121.5 nM[1].
RD-23 (1-50 nM; 24 h) inhibits downstream Shc activation in a concentration-dependent manner in Ba/F3-KIF5B-RETG810C cells after 24 h of treatment[1].
RD-23 (10-40 nM; 48 h) induces dose-dependent apoptosis in Ba/F3-KIF5B-RETG810C cells after 48 h of treatment, with 71.3% of cells apoptotic at a concentration of 40 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Ba/F3-KIF5B-RETG810C
-
Concentration:1, 10, 20 and 50 nM
-
Incubation Time:24 h
-
Result:Inhibited activation of downstream Shc signaling in a concentration-dependent manner, with reduced levels of phosphorylated Shc corresponding to reduced RET protein levels.
-
Cell Line:Ba/F3-KIF5B-RETG810C
-
Concentration:10, 20 and 40 nM
-
Incubation Time:48 h
-
Result:Induced dose-dependent apoptosis, with apoptotic cell percentages reaching 34.1% (10 nM), 55.4% (20 nM), and 71.3% (40 nM), which were significantly higher than the control group's 6.7%.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nu/nu (female, 6 to 8 weeks old, subcutaneously implanted with 5 × 106 Ba/F3-KIF5B-RETG810C cells)[1]
-
Dosage:10 mg/kg
-
Administration:p.o.; once or twice daily; 10 days
-
Result:Induced 62.3% tumor growth inhibition at 10 mg/kg p.o. once daily.
Induced 85.1% tumor growth inhibition at 10 mg/kg p.o. twice daily.
Induced degradation of the RET protein in tumor tissue.
Did not cause significant body weight changes during treatment.
Chemical Information
-
CAS No. 3053537-06-4
-
Molecular Weight 913.08
-
Formula C52H56N12O4
-
SMILES
N#CC1=C2C(C3=CC=C(N=C3)N4CC5CC(C4)N5CC6=CC=C(N=C6)OC)=CC(N7CCC(CC7)N8CCN(CC8)CCCC#CC9=CC=CC%10=C9CN(C%10=O)C(C(N%11)=O)CCC%11=O)=CN2N=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)